Company: Bayer AG
Job title: Senior Scientist, Small Molecule Innovation
Benjamin Bader is a senior biochemist and cell-biologist at Small Molecule Innovation Bayer AG. Engaged in Assay Development & HTS for Lead Discovery projects his research has been focused on pharma oncology projects in the areas of signal transduction (Ras-pathway), cell cycle (spindle checkpoint), immune-oncology, DNA-damage signalling and hormone-dependent tumours. Prior to his career in large pharma starting at Schering AG in 2001, he worked for the German biotech Vasopharm. Benjamin graduated in 1996 in human biology at the University of Marburg, Germany, followed by a PhD at the Max-Planck-Institute for Molecular Physiology in Dortmund, Germany, where he studied lipid modification of Ras proteins together with Prof. Wittinghofer and Prof. Waldmann.
Disruption of the RAS-SOS1 Interaction – Enabling Lead Discovery by a Combination of High-Throughput and Fragment Screening 12:15 pm
Combination of high-throughput & fragment screening enabled a new approach to target KRAS Structure-guided optimization of potent and selective SOS1 inhibitors Cellular data support a possible combination potential of SOS1 inhibitors with covalent inhibitors of KRASG12CRead more
day: Day One